Viking Therapeutics Inc diskutieren
Viking Therapeutics Inc
WKN: A12GD6 / Name: Viking / Aktie / Biotechnologie & medizinische Forschung / Small Cap /
VK5211 akute Hüftfraktur
Biotechnologie und medizinische SecteurRecherche
Viking Therapeutics is undervalued
At the end of November the company announced positive results from a 12-week mid-stage study evaluating VK5211 in patients who recently suffered a hip fracture. The drug candidate is an orally
available, non-steroidal selective androgen receptor modulator (SARM) which was created to stimulate bone and muscle formation with a reduction of activity in peripheral tissues.
Jay Magaziner, PhD, MSHyg, Professor and Chair, Department of Epidemiology and Public Health at the University of Maryland School of Medicine, had the following commentary:
The degree of improvement in lean body mass in this group of older persons who are prone to losing muscle is impressive. Having a drug like this available that can be taken easily and safely soon after hip fracture would provide a valuable adjunct to other therapeutic strategies such as physical therapy and a protein-rich diet to boost patients' chances for resuming usual activities.
In the future one can expect further updates on endpoints including exploratory measures of functional performance. Considering that the drug candidate could have blockbuster potential and even if peak sales were $500 million to be ultra conservative, based on this one candidate alone it would seem the company is undervalued. According to the company there are around 300,000 patients per year in the United States for the target indication.
Biotechnologie und Medizintechnik SecteurRecherche Agenda 12/02 | 03.00 presentatio
Viking Therapeutics, Inc. ist ein biopharmazeutisches Unternehmen in der klinischen Phase, die leiden , bei der Entwicklung neuer Therapien für Patienten greift von metabolischen und endokrinen Erkrankungen.
Sein VK5211 klinisches Programm behandelt Patienten , die von einer Fraktur der Operation von nicht-elektiven Hüft- erholen.
Er ist spezialisiert auf die Entwicklung von VK2809 und VK0214.
Das Unternehmen wurde von Brian Lian und Michael A. Dinerman September 2012 24, gegründet und befindet sich in San Diego, Kalifornien.
Anzahl der Mitarbeiter: 12 Personen.
Viking Therapeutics a possible 10-bagger - William Blair
tamam stimmt am 30.04.2018 der Buy-Einschätzung von stratec mit dem Kursziel 8,2$ zu.
Überschrift: Viking Therapeutics is undervalued
Man muss sich zwischendurch auch mal trennen können: Ich beende für heute...
Viking Therapeutics is still undervalued
Viking Therapeutics recently released positive data from an NAFLD clinical trial.
The NAFLD market is a massive one with serious unmet medical need.
After digging into the company's most recent financial report, I was pleasantly surprised.
I believe that Viking Therapeutics has incredible upside potential.
At the end of November the company announced positive results from a 12-week mid-stage study evaluating VK5211 in patients who recently suffered a hip fracture. The drug candidate is an orally
available, non-steroidal selective androgen receptor modulator (SARM) which was created to stimulate bone and muscle formation with a reduction of activity in peripheral tissues.
Jay Magaziner, PhD, MSHyg, Professor and Chair, Department of Epidemiology and Public Health at the University of Maryland School of Medicine, had the following commentary:
The degree of improvement in lean body mass in this group of older persons who are prone to losing muscle is impressive. Having a drug like this available that can be taken easily and safely soon after hip fracture would provide a valuable adjunct to other therapeutic strategies such as physical therapy and a protein-rich diet to boost patients' chances for resuming usual activities.
In the future one can expect further updates on endpoints including exploratory measures of functional performance. Considering that the drug candidate could have blockbuster potential and even if peak sales were $500 million to be ultra conservative, based on this one candidate alone it would seem the company is undervalued. According to the company there are around 300,000 patients per year in the United States for the target indication.
08.10.2018
The results demonstrated that treatment with VK2809 led to anoverall improvement in liver health highlighted by restoration of autophagy, reduction in steatosis, and improvements in inflammation and
liver size. The study investigators concluded that these histological improvements are potentially relevant to non-alcoholic fatty liver disease, including non-alcoholic steatohepatitis, due to certain similarities between those conditions and GSD Ia.
Importantly, this study also demonstrated indications of reduced inflammatory signalling following treatment with VK2809.
SecteurRecherche biotechnologique et médicale Agenda 06/03 Publication de résultats
Viking Therapeutics, Inc. est une société biopharmaceutique au stade clinique qui développe de nouvelles thérapies pour les patients souffrant de troubles métaboliques et endocriniens.
Son programme clinique VK5211 traite les patients en convalescence après une chirurgie pour fracture de la hanche non élective.
Elle est également spécialisée dans le développement de VK2809 et VK0214.
La société a été fondée par Brian Lian et Michael A. Dinerman le 24 septembre 2012 et son siège social est situé à San Diego, Californie.
Nombre d'employés : 11 personnes.
Könnte
was werden.
SecteurRecherche biotechnologique et médicale Agenda 06/03 Publication de résultats
Viking Therapeutics, Inc. est une société biopharmaceutique au stade clinique qui développe de nouvelles thérapies pour les patients souffrant de troubles métaboliques et endocriniens.
Son programme clinique VK5211 traite les patients en convalescence après une chirurgie pour fracture de la hanche non élective.
Elle est également spécialisée dans le développement de VK2809 et VK0214.
La société a été fondée par Brian Lian et Michael A. Dinerman le 24 septembre 2012 et son siège social est situé à San Diego, Californie.
Nombre d'employés : 11 personnes.
Neueste Beiträge
me8 in Avenue Therapeutics Inc. diskutieren